Cantourage Group SE: Strong growth continues – another monthly sales record in June 2024

Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement need to be observed.

Cantourage Group SE: Strong growth continues – another monthly sales record in June 2024

• High growth dynamics since the partial legalization of cannabis in Germany came into force continue and gain further momentum
• Monthly sales increased to EUR 4.1 million in June 2024
• Cantourage and Telecan establish themselves as a main point of contact for patients

Berlin, July 03, 2024 – Cantourage Group SE (hereinafter referred to as “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), a leading European company for the production and distribution of cannabis, once again achieved record monthly sales in June 2024. Sales revenue of EUR 4.1 million was generated in the period. Cantourage had already set a new record for sales in the previous month (sales in May 2024: EUR 3.5 million) as a result of the noticeable increase in demand for high-quality cannabis products.

Since the partial legalization of cannabis in Germany came into effect in April 2024, the demand for cannabis products in pharmacies has increased significantly. At the same time, Cantourage is also continuously expanding its collaboration with doctors as part of its online platform for cannabis on prescription, Telecan (www.telecan.eu). This provides more and more patients with a simple and direct route to cannabis therapy. Overall, Cantourage’s business has grown dynamically in all core areas most recently.

“Thanks to our flexible business model, we have prepared for the ongoing liberalization of cannabis in Germany and other European countries at an early stage in recent years. In doing so, we were able to bring on board many well-known cannabis growers from all over the world as partners and also expand our own production capacities in time for the expected increase in demand. We have benefited greatly from this, particularly since April 2024. We now expect the positive growth momentum from the second quarter to continue in the second half of 2024,” said Philip Schetter, CEO of Cantourage.

About Cantourage

Cantourage is a leading European producer and distributor of cannabis flowers and cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under ticker symbol “HIGH.”

Further information: www.cantourage.com

This announcement does not constitute a public offer or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

Press contact at Cantourage:

Frederick Steudemann

Phone: +49 (0)30 4701 350 - 50

steudemann@cantourage.com